{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:03:24Z","timestamp":1793833404830,"version":"4.6.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.canlet.2011.09.026","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T01:52:34Z","timestamp":1317347554000},"page":"176-184","source":"Crossref","is-referenced-by-count":49,"title":["Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases"],"prefix":"10.1016","volume":"314","author":[{"given":"Osama","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Tiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzur","family":"Murshed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana V.","family":"Komarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2011.09.026_b0005","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/cncr.21778","article-title":"Metastatic patterns in adenocarcinoma","volume":"106","author":"Hess","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0010","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in metastatic breast cancer","volume":"22","author":"Hamaoka","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.09.026_b0015","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.09.026_b0020","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1200\/JCO.2010.28.6559","article-title":"Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy","volume":"28","author":"Kerba","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.09.026_b0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0030","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/01.blo.0000093844.72468.f4","article-title":"Breast cancer metastasis to bone: it is not all about PTHrP","author":"Bendre","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.canlet.2011.09.026_b0035","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.09.026_b0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yexcr.2007.09.021","article-title":"Metastatic breast cancer induces an osteoblast inflammatory response","volume":"314","author":"Kinder","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2011.09.026_b0045","doi-asserted-by":"crossref","first-page":"31427","DOI":"10.1074\/jbc.M110.114496","article-title":"Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of g-secretase","volume":"285","author":"Fong","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.09.026_b0050","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/cbt.5.9.3306","article-title":"Pathophysiology of bone metastases","volume":"5","author":"Berenson","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2011.09.026_b0055","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/carcin\/bgp227","article-title":"Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer","volume":"30","author":"Chen","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2011.09.026_b0060","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ijc.20056","article-title":"Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte\/macrophage colony-stimulating factor","volume":"109","author":"Morgan","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0065","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bone.2008.03.026","article-title":"Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation","volume":"43","author":"Guo","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.canlet.2011.09.026_b0070","doi-asserted-by":"crossref","first-page":"33662","DOI":"10.1074\/jbc.M109.010785","article-title":"Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+\/protein kinase C and transforming growth factor-beta\/MAPK signaling pathways","volume":"284","author":"Tiedemann","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.09.026_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50","article-title":"Molecular mechanisms of tumor-bone interactions in osteolytic metastases","volume":"10","author":"Chirgwin","year":"2000","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.canlet.2011.09.026_b0080","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdp261","article-title":"Third consensus on medical treatment of metastatic breast cancer","volume":"20","author":"Beslija","year":"2009","journal-title":"Ann. Oncol."},{"issue":"Suppl. 4","key":"10.1016\/j.canlet.2011.09.026_b0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/annonc\/mdp115","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Cardoso","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.09.026_b0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0095","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2011.09.026_b0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bone.2010.09.006","article-title":"Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis","volume":"48","author":"Hussein","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.canlet.2011.09.026_b0105","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","article-title":"Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy","volume":"14","author":"Lipton","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.09.026_b0110","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1074\/jbc.M410480200","article-title":"Akt1\/Akt2 and mammalian target of rapamycin\/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors","volume":"280","author":"Sugatani","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canlet.2011.09.026_b0115","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","article-title":"M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase","volume":"10","author":"Glantschnig","year":"2003","journal-title":"Cell Death Differ."},{"issue":"Suppl. 1","key":"10.1016\/j.canlet.2011.09.026_b0120","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1038\/sj.cdd.4401399","article-title":"Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol\/lipoproteins","volume":"11","author":"Luegmayr","year":"2004","journal-title":"Cell Death Differ."},{"issue":"Suppl. 2","key":"10.1016\/j.canlet.2011.09.026_b0125","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/onc.2009.352","article-title":"Common corruption of the mTOR signaling network in human tumors","volume":"27","author":"Menon","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.09.026_b0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1684\/bdc.2010.1069","article-title":"mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma","volume":"97","author":"Ravaud","year":"2010","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0135","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.09.026_b0140","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.09.026_b0145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2007.10.003","article-title":"The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics","volume":"44","author":"Awada","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0150","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.09.026_b0155","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1158\/1535-7163.MCT-10-0489","article-title":"Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction","volume":"9","author":"Okui","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2011.09.026_b0160","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/0008-5472.CAN-05-3119","article-title":"Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically","volume":"66","author":"Fisher","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.09.026_b0165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2008.10.047","article-title":"Inhibition of bone resorption and growth of breast cancer in the bone microenvironment","volume":"44","author":"Buijs","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.canlet.2011.09.026_b0170","doi-asserted-by":"crossref","unstructured":"B.A. Pulaski, S. Ostrand-Rosenberg, Mouse 4T1 Breast Tumor Model, in: Current Protocols in Immunology, John Wiley & Sons, Inc., 2001.","DOI":"10.1002\/0471142735.im2002s39"},{"key":"10.1016\/j.canlet.2011.09.026_b0175","first-page":"4418","article-title":"The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases","volume":"61","author":"Hiraga","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.09.026_b0180","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/en.140.10.4451","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2011.09.026_b0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pros.10091","article-title":"Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells","volume":"52","author":"Corey","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2011.09.026_b0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10585-004-2869-0","article-title":"The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft","volume":"21","author":"Kiefer","year":"2004","journal-title":"Clin. Exp. Metast."},{"key":"10.1016\/j.canlet.2011.09.026_b0195","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1595::AID-CNCR10>3.0.CO;2-V","article-title":"Radiologic diagnosis of bone metastases","volume":"80","author":"Rosenthal","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10585-007-9056-z","article-title":"Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases?","volume":"24","author":"Vassiliou","year":"2007","journal-title":"Clin. Exp. Metast."},{"key":"10.1016\/j.canlet.2011.09.026_b0205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-0981-1","article-title":"Prognostic factors for skeletal complications from metastatic bone disease in breast cancer","volume":"123","author":"Brown","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2011.09.026_b0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.1988.272","article-title":"Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)","volume":"58","author":"Coleman","year":"1988","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0215","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.09.026_b0220","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiol.2471070567","article-title":"Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET\/CT","volume":"247","author":"Tateishi","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.canlet.2011.09.026_b0225","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/1078-0432.CCR-03-0043","article-title":"Determinants of rapamycin sensitivity in breast cancer cells","volume":"10","author":"Noh","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.09.026_b0230","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ejca.2010.01.014","article-title":"Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study","volume":"46","author":"Zeng","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2011.09.026_b0235","article-title":"Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73","author":"Wong","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2011.09.026_b0280","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.27504","article-title":"Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis","volume":"62","author":"Cejka","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.canlet.2011.09.026_b0240","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.09.026_b0245","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood-2008-02-137430","article-title":"Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells","volume":"112","author":"Ohtani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.09.026_b0250","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1126\/science.283.5399.222","article-title":"STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation","volume":"283","author":"Welte","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.canlet.2011.09.026_b0255","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1073\/pnas.0507350103","article-title":"Stat5a\/b are essential for normal lymphoid development and differentiation","volume":"103","author":"Yao","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2011.09.026_b0260","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1074-7613(00)80025-4","article-title":"Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells","volume":"10","author":"Moriggl","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2011.09.026_b0265","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.4049\/jimmunol.159.6.2580","article-title":"Immunocompromised tumor-bearing mice show a selective loss of STAT5a\/b expression in T and B lymphocytes","volume":"159","author":"Pericle","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2011.09.026_b0270","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcb.21411","article-title":"Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells","volume":"103","author":"Singha","year":"2008","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.canlet.2011.09.026_b0275","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1002\/jbmr.114","article-title":"NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells","volume":"25","author":"Martin","year":"2010","journal-title":"J. Bone Miner. Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511005726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511005726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:57:19Z","timestamp":1686373039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383511005726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0304383511005726"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2011.09.026","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}